bendamustine hydrochloride · Azurity · NDA 212209
Vivimusta
Earliest generic entry, as listed
29 Jul 2042
Blocked by patent: US 11707450, US 11844784, US 12208086, US 12419867.
Listed patents · 4 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 11707450 | drug product · sets the listed date | 29 Jul 2042 |
| US 11844784 | drug product · sets the listed date | 29 Jul 2042 |
| US 12208086 | drug product · sets the listed date | 29 Jul 2042 |
| US 12419867 | drug product · sets the listed date | 29 Jul 2042 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 212209 · 001 · RLD | solution, intravenous | 100MG/4ML (25MG/ML) | 29 Jul 2042 |